Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody-drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced the retirement of
Anna Protopapas, President and CEO, effective September 10, 2023,
and the appointment of Martin Huber, M.D., current member of the
Board of Directors, as President and CEO, effective September 11,
2023. Dr. Huber and Ms. Protopapas will both remain members of
Mersana’s Board of Directors following the transition.
“With his extensive track record of bringing new medicines to
patients with cancer and demonstrated leadership capabilities
across both small and large biopharmaceutical organizations, we
believe Marty is ideally suited to lead Mersana as it advances its
innovative next-generation ADC platforms and product candidates.
Additionally, his experience on Mersana’s Board of Directors,
including his work with the executive team, should facilitate a
seamless transition,” said David Mott, Chairman of Mersana’s Board
of Directors. “On behalf of the Board of Directors and the entire
organization, I would like to express our sincere appreciation for
Anna’s leadership of Mersana over the past eight years. Beyond the
company’s platforms, pipeline, collaborations and financial
resources, she has built a strong team and culture that is driven
by the knowledge that patients are waiting for new treatment
options. We look forward to her continued contributions on the
Board of Directors.”
Dr. Huber has been a member of Mersana’s Board of Directors
since 2020 and joins the company from Xilio Therapeutics, Inc.,
where he most recently served as President, Head of R&D and,
prior to that, as Chief Medical Officer. Before joining Xilio, he
served as Chief Medical Officer at TESARO, Inc., and after TESARO’s
acquisition by GlaxoSmithKline plc, as Senior Vice President,
Clinical. Prior to TESARO, Dr. Huber served as Vice President,
Oncology Clinical Research at Merck Research Laboratories. Earlier,
he served in roles of increasing responsibility at Schering-Plough,
Hoffmann-La Roche and Rhone-Poulenc Rorer, where he led teams in
the areas of oncology clinical development, drug safety and
pharmacovigilance. His work has contributed to the approval of such
oncology medicines as docetaxel, dostarlimab, niraparib,
pembrolizumab and trastuzumab. He began his career as an Assistant
Professor of Oncology at the University of Texas M.D. Anderson
Cancer Center. Dr. Huber received his medical degree from Baylor
College of Medicine.
Martin Huber, M.D., has been named President and Chief Executive
Officer of Mersana Therapeutics, Inc., effective September 11,
2023.
“I am thrilled about the opportunity to lead Mersana and build
upon the strong foundation that Anna and the team have
established,” said Dr. Huber. “With innovative ADC platforms and
multiple product candidates in development, including our B7-H4 ADC
XMT-1660 which we believe is progressing toward potential
proof-of-concept Phase 1 data, I am excited by Mersana’s
opportunity to make a meaningful difference for patients in
need.”
Mersana also announced today additional changes to the company’s
executive team. Brian DeSchuytner, who joined the company in 2019
and has served as Senior Vice President, Chief Financial Officer
(CFO) since 2021, has been named Senior Vice President, Chief
Operating Officer and CFO. He will continue to serve as the
company’s principal financial officer while overseeing its finance,
investor relations, business development, information technology
and human resources functions. Mohan Bala, Ph.D., who has served as
Senior Vice President, Strategic Product Planning & Program
Leadership since 2021, has been named Senior Vice President, Chief
Development Officer and will lead the company’s clinical and
translational medicine, clinical operations, biometrics, product
planning and program leadership functions. Additionally, Ashish
Mandelia, who joined the company as Vice President, Controller in
2019, has been appointed Vice President, Chief Accounting
Officer.
In conjunction with these changes, Chief Medical Officer Arvin
Yang, M.D., and Chief People Officer Carla Poulson will be
departing Mersana, effective September 29, 2023.
“It has been an honor to work with each of these individuals and
the broader Mersana team,” said Ms. Protopapas. “I am enormously
proud of the organization and the culture we have built and am
confident that, under Marty’s leadership and the guidance of our
talented executive team, the company’s future will be bright. I
want to express our sincere thanks to Arvin and Carla for their
commitment and significant contributions to Mersana. We wish them
the very best on their next ventures.”
About Mersana TherapeuticsMersana Therapeutics
is a clinical-stage biopharmaceutical company focused on the
development of novel antibody-drug conjugates (ADCs) and driven by
the knowledge that patients are waiting for new treatment options.
The company has developed proprietary cytotoxic (Dolasynthen) and
immunostimulatory (Immunosynthen) ADC platforms that are generating
a pipeline of wholly-owned and partnered product candidates with
the potential to treat a range of cancers. Its pipeline includes
XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an
Immunosynthen ADC targeting a novel epitope of human epidermal
growth factor receptor 2 (HER2). Mersana routinely posts
information that may be useful to investors on the “Investors &
Media” section of its website at www.mersana.com.
Forward-Looking StatementsThis press release
contains “forward-looking” statements and information within the
meaning of the Private Securities Litigation Reform Act of 1995.
These statements may be identified by words such as “aims,”
“anticipates,” “believes,” “could,” “estimates,” “expects,”
“forecasts,” “goal,” “intends,” “may,” “plans,” “possible,”
“potential,” “seeks,” “will” and variations of these words or
similar expressions, although not all forward-looking statements
contain these words. Forward-looking statements in this press
release include, but are not limited to, statements regarding
Mersana’s anticipated executive transitions; the progression of its
clinical trial of XMT-1660; and the development and potential of
Mersana’s product candidates, platforms, technology and pipeline of
ADC candidates. Mersana may not actually achieve the plans,
intentions or expectations disclosed in these forward-looking
statements, and you should not place undue reliance on these
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
these forward-looking statements as a result of various factors,
including, among other things, uncertainties inherent in research
and development; in the advancement, progression and completion of
clinical trials and in the clinical development of Mersana’s
product candidates, including XMT-1660; the risk that Mersana may
not realize the intended benefits of its platforms, technology and
collaborations; and other important factors, any of which could
cause Mersana’s actual results to differ from those contained in
the forward-looking statements, that are described in greater
detail in the section entitled “Risk Factors” in Mersana’s
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission (“SEC”) on August 8, 2023, as well as in other
filings Mersana may make with the SEC in the future. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Mersana expressly disclaims any
obligation to update any forward-looking statements contained
herein, whether because of any new information, future events,
changed circumstances or otherwise, except as otherwise required by
law.
Contact:Jason Fredette
617-498-0020jason.fredette@mersana.com
A photo accompanying this announcement is available
at: https://www.globenewswire.com/NewsRoom/AttachmentNg/feb03782-4451-4127-857f-512aab5766d3
Mersana Therapeutics (NASDAQ:MRSN)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Mersana Therapeutics (NASDAQ:MRSN)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024